TUCSON, Ariz.--(BUSINESS WIRE)--Calimmune, Inc., a clinical-stage gene therapy company, today announced a license agreement with Cincinnati Children’s Hospital Medical Center (Cincinnati Children’s) ...
Poster talk will present safety and efficacy data for ENaBL-T, a lentiviral vector for in vivo engineering of BCMA CAR T cells, which supported the first in vivo BCMA CAR-T cell therapy clinical trial ...
Bluebird bio has suspended two clinical trials of its sickle cell disease gene therapy after participants developed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). During the pause, ...
100% overall survival and ≥95% event-free survival observed at two and three years following one-time treatment with lentiviral HSC gene therapy 50 total participants represent largest published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback